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Background: This study was devised to assess the performance of anti-ribosomal P (anti-Rib-P) antibodies in the
diagnosis of systemic lupus erythematosus (SLE) and the association of these antibodies with the clinical features of
SLE.
Methods: We used a fluorescence enzyme immunoassay to determine anti-Rib-P levels in an SLE group, a
rheumatic disease control (RDC) group (rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis and
juvenile idiopathic arthritis), and a healthy control (HC) group. We also determined anti-Smith antigen (anti-Sm) and
anti-double-stranded DNA (anti-dsDNA) antibody levels. Receiver operating characteristic (ROC) curves were
constructed and the best cut-off points for positivity were determined. Using regression analysis, the relationship
between clinical variables and autoantibody levels was analyzed.
Results: In total, 127 patients with SLE, 256 controls with other rheumatic diseases, and 100 HCs were studied. Anti-
Rib-P autoantibodies were positive in 18 (14.2%) of the patients with SLE (mean concentration of 30.6 ± 46.9 U/ml)
and in 2 patients with RA (0.8% of the RDC group). In addition, 12 patients with SLE (9.4%) were positive for anti-
Sm (31.1 ± 40.8 U/ml) and 63 (49.6%) were positive for anti-dsDNA autoantibodies (88.4 ± 88.5 U/ml). When we
assessed the 18 patients with SLE who had tested positive for anti-Rib-P, we found that 4 of these were positive for
anti-Rib-P only, whereas 12 were positive for anti-Rib-P plus anti-dsDNA, and 2 were positive for all three antibodies.
There were no samples positive for anti-Rib-P plus anti-Sm. The specificity, sensitivity, positive likelihood ratio, and
negative likelihood ratio of anti-Rib-P for SLE diagnosis were 99.4%, 14.2%, 23.7%, and 0.86%, respectively.
Caucasian ethnicity was associated with lower anti-Rib-P antibody levels. No relation was found between anti-Rib-P
levels and neuropsychiatric or other clinical features.
Conclusions: Anti-Rib-P autoantibodies have high specificity for SLE, and measurement of these might improve the
accuracy of SLE diagnosis. In this study, we found that Caucasian ethnicity was associated with lower anti-Rib-P
antibody levels.
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Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease characterized by multi-organ involve-
ment and by the production of autoantibodies directed
against a variety of nuclear and cytoplasmic antigens
[1,2]. Autoantibodies can be detected in patients’ sera
years before the diagnosis of SLE is made [3]. Some anti-
bodies are relevant to diagnosis, whereas others are asso-
ciated with prognostic features or disease activity status
[2,4].
Antibodies against double-stranded DNA (anti-
dsDNA) and Smith antigen (anti-Sm) are considered
very specific for SLE diagnosis, and both are part of the
immunologic classification criteria for this disease [5].
Furthermore, high levels of anti-dsDNA are associated
with higher disease activity in SLE [6].
One subset of SLE-specific autoantibodies is directed
against ribosomal P (Rib-P) phosphoproteins [2]. The
Rib-P antigen consists of three protein components of
the 60S ribosomal subunit designated P0 (38 kDa), P1
(19 kDa), and P2 (17 kDa). A pentameric complex of
one copy of P0 and two copies each of P1 and P2 inter-
acts with the 28S rRNA molecule to form a GTPase do-
main that is active during the elongation step of protein
translation [7-12]. The major immunoreactive epitope of
these ribosomal antigens has been localized to the 22
amino acid carboxy-terminal domain, which is present
in all three proteins, and contains two phosphorylated
serine residues proteins [2,8-14].
Anti-Rib-P antibodies are directed against the three
subunits [2,9,15], and are able to penetrate certain cells,
binding to ribosomal proteins and blocking protein syn-
thesis [15]. Anti-Rib-P antibodies enhance the produc-
tion of tumor necrosis factor (TNF) and interleukin
(IL)-6 by activated monocytes and also upregulate the
expression of TNF and IL-6 messenger RNA in activated
monocytes, indicating that human peripheral blood
monocytes express the ribosomal P epitope upon activa-
tion [15].
Ethnic background may influence the likelihood of
anti-Rib-P antibodies occurring in patients with SLE,
with the frequency ranging from 6% to 46% in different
ethnic groups [2,7,11,14-16]. In most ethnic groups,
anti-Rib-P antibodies are present in 6 to 20% of patients,
whereas 36% of Chinese patients with SLE were reported
to be positive [7,11,12,15].
Anti-Rib-P antibodies seem to be highly specific for
SLE, and might also be a marker for SLE disease activity
[12,14,15]. The presence of anti-Rib-P antibodies in pa-
tients with SLE has been reported to be associated with
younger age at disease onset, multiple organ involve-
ment, and an overall severe disease course [8], including
presence of central nervous system involvement
[2,4,7,11,12,15], nephritis [2,7,12,15], photosensitivity [2],malar rash [2], and hepatic involvement [2,7,12]. More-
over, it has become evident that anti-Rib-P antibodies
are more prevalent in juvenile-onset than in adult onset
SLE [11,12]. Bonfa et al. first assessed the association of
anti-Rib-P antibodies with psychiatric features in pa-
tients with psychosis secondary to SLE [17]; however,
other studies have not confirmed this association [7,8].
We hypothesized that anti-Rib-P autoantibodies might
be useful for SLE diagnosis. To test this hypothesis, we
used a new fluorescence enzyme immunoassay (FEIA)
kit to quantify levels of anti-Rib-P in patients with SLE,
controls with other rheumatic diseases (rheumatic di-
sease control (RDC) group, which included rheumatoid
arthritis (RA), juvenile idiopathic arthritis (JIA), ankylo-
sing spondylitis (AS), and psoriatic arthritis (PsA)), and
healthy controls (HC group).
Methods
Ethics approval
The study was conducted in accordance with the regula-
tions governing clinical trials such as the Declaration of
Helsinki, as amended in Seoul (2008), and was approved
by the ethics committees of the Centro Hospitalar Lisboa
Norte, Hospital de Santa Maria and the Hospital Garcia
de Orta. All participants signed a written informed con-
sent form before any protocol-specific procedure was car-
ried out.
Patients
For this study, we used serum samples from Biobank
(Instituto de Medicina Molecular, Lisboa, Portugal), col-
lected between May 2007 and December 2009. Samples
were selected from patients with the following diagnoses
fulfilling the criteria of the relevant classifications: SLE
(revised American College of Rheumatology (ACR) cri-
teria, 1997), RA (revised American Rheumatism Asso-
ciation (ARA) criteria, 1987), JIA (International League
of Associations for Rheumatology (ILAR) classification,
second revision, 2001), AS (modified New York criteria,
1984) and PsA (modified European Spondyloarthropathy
Study Group (ESSG) criteria, 2006). Samples from
healthy volunteers were used as the HC group.
In total 127 patients with SLE, 256 RDCs (100 RA, 99
AS, 34 JIA, and 23 PsA), and 100 HCs were studied.
Data on age, ethnicity, and gender were collected. For
patients with SLE, the following data were obtained at
the time of blood sample collection: age at disease diag-
nosis, disease duration, cumulative clinical features (in
accordance with ACR classification criteria), presence of
autoantibodies (anti-dsDNA, anti-Sm, anti-cardiolipin,
anti-SSA, anti-SSB, and anti-ribonucleoprotein (anti-
RNP) antibodies), current medication (including current
dosage of corticosteroids and use of immunosuppres-
sants, current disease activity (evaluated using the
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2000 (SLEDAI2K) [18]), and cumulative organ damage
(scored using the Systemic Lupus International Collabo-
rating Clinics/ACR Damage Index (SLICC) [19]). Clinical
features, particularly the occurrence of neuropsychiatric
lupus syndromes in accordance with the ACR nomencla-
ture [20], disease activity, and accumulated organ damage
were assessed semi-annually thereafter.Assay
Quantification of anti-Rib-P, anti-Sm and anti-dsDNA
antibodies was carried out using FEIA kits (EliA™ Rib-P,
EliA™ Sm, and EliA™ dsDNA; Phadia, Uppsala, Sweden;
now part of Thermo Fisher Scientific) for in vitro diagno-
sis in accordance with the manufacturer’s instructions.Statistical analysis
Results are reported as mean ± standard deviation for
continuous variables or proportion for categorical varia-
bles. Anti-Rib-P, anti-Sm and anti-dsDNA concentra-
tions are presented in U/ml.
Receiver operating characteristic (ROC) curves were
performed for each test comparing the results from the
patients with SLE with those of the HC or RDC groups.
For both ROC curves for each antibody, a cut-off point
was determined as the value of the parameter corres-
ponding to the highest sensitivity without lowering the
specificity. The area under the curve (AUC) was also
determined.
Differences between the SLE and control groups were
assessed using the t-test for continuous variables or χ2
or Fisher’s exact test for proportions.
The association between clinical variables and the vari-
ous antibodies was investigated for patients with SLE
using univariate followed by multivariate linear regres-
sion analyses. All variables relating to the studied out-
come in the univariate analyses at P ≤ 0.20 were
considered potential predictors, and were entered into
the multivariate linear regression models along with
neuropsychiatric features, because of their previously de-
scribed association with these antibodies. The selection
of covariates was stepwise by backward selection.
Statistical calculations were performed using SPSS
statistical software (version 15.0; SPSS Inc., Chicago, IL,Table 1 Demographic characteristics of the studied populatio
SLE HC
Age, years 43.6 ± 14.1 43.1 ± 14.6 51.7
Females, n (%) 120 (96.0) 91 (91.9) 99
Caucasian, n (%) 110 (88.0) 98 (99.0) 90
Abbreviations: AS, ankylosing spondylitis; HC, healthy control; JIA, juvenile idiopathi
erythematosus. Values represent mean ± standard deviation for years, and proportioUSA) and a two-tailed P-value of < 0.05 was considered
significant.
Results
The demographic characteristics of all studied subjects are
presented in Table 1. Patients with SLE had a mean age at
disease diagnosis of 34.2 ± 14.5 years, disease duration of
8.3 ± 6.5 years (range 0.5 to 34 years), mean SLEDAI2K of
3.3 ± 4.2, and SLICC damage score of 1.1 ± 2.1 at baseline
evaluation. Of the 127 patients with SLE, 79 (62.2%) were
receiving treatment with corticosteroids (mean daily do-
sage of prednisolone 12.4 mg), 90 (71%) with antima-
larials, 50 (39%) with immunosuppressants, and 1 with a
monoclonal antibody (rituximab).
ROC curves were constructed to obtain the most ad-
equate cut-off values for the Portuguese population; these
curves are of particular relevance for the new anti-Rib-P
test kit. Curves were also constructed for the other tests
for coherence analysis. The curves are presented in Figure 1
with the AUC and the corresponding P-values identified.
For both the anti-Rib-P and anti-Sm tests, the cut-off
values after analysis of the ROC curves were 4.45 U/ml
and 3.4 U/ml, respectively. For anti-dsDNA, the cut-off
value given by the manufacturer (15 U/ml) was used be-
cause it corresponds to the value obtained from the ROC
curves. With these adjustment in cut-off values, we identi-
fied a higher number of patients with SLE who were posi-
tive for either anti-Rib-P or anti-Sm, without incurring
more false-positive results in the control groups than we
did with the manufacturer cut-off points (data not shown).
We found that the levels of anti-Rib-P autoantibodies
were significantly higher in the SLE group (mean concen-
tration of 4.9 ± 20.2 U/ml) than in the HC group (0.07 ±
0.21 U/ml; P = 0.016) or the RDC group (0.6 ± 1.8 U/ml;
P = 0.017). In 18 samples of the SLE group (14.2%), anti-
Rib-P was above the cut-off value of 4.45 U/ml for positi-
vity (mean concentration of 30.6 ± 46.9 U/ml). Of note, in
the RDC group, two patients with RA (0.8%) were positive
for anti-Rib-P autoantibodies (18.9 ± 9.8 U/ml), whereas
none of the HCs tested positive for this antibody.
The mean concentration of anti-Sm antibodies for the
whole SLE group was 2.8 ± 13.8 U/ml, and 12 of these
positive samples (9.4%) had a significantly higher mean
concentration (31.1 ± 40.8 U/ml) than those of the HC
group (0.02 ± 0.11 U/ml; P = 0.028) or the RDC groupn
Rheumatic disease control
RA JIA AS PsA
± 13.9 13.6 ± 7.2 41.9 ± 10.7 49.8 ± 11.1
(99.0) 18 (52.9) 26 (27.1) 9 (39.1)
(90.0) 30 (88.2) 95 (97.9) 20 (90.9)
c arthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus
ns for categorical variables.
Figure 1 (See legend on next page.)
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Figure 1 Receiver operating characteristic (ROC) curves for the three antibodies quantified. (A) Anti-ribosomal P (anti-Rib-P), (B) anti-Smith
(anti-Sm), and (C) anti-double-stranded DNA (anti-dsDNA) antibodies. The curves represent the sensitivity and specificity for the systemic lupus
erythematosus (SLE) group versus the healthy control group, and for the SLE group versus the rheumatic disease control group. For each curve,
the area under the curve (AUC) and corresponding P-value are indicated. The flag indicates the cut-off established by the manufacturer and the
asterisk indicates the new cut-off calculated from the curves (4.45 U/ml for anti-Rib-P and 3.4 U/ml for anti-Sm antibodies; the anti-dsDNA cut-off
did not change).
Carmona-Fernandes et al. BMC Medicine 2013, 11:98 Page 5 of 8
http://www.biomedcentral.com/1741-7015/11/98(0.1 ± 0.3 U/ml; P = 0.035). Positive results (above 3.4 U/ml)
for anti-Sm autoantibodies were found only in the SLE
group.
Patients with SLE also had a significantly greater mean
concentration of anti-dsDNA antibodies (44.6 ± 73.8 U/ml)
than found in the HC group (3.5 ± 8.1 U/ml; P < 0.001) or
the RDC group (2.6 ± 4.2 U/ml; P < 0.001). Of the 127 pa-
tients with SLE, 63 (49.6%) were positive for anti-dsDNA
(mean concentration 88.4 ± 88.5 U/ml.), compared with 6
samples (6.0%) in the HC group and 5 samples (2.0%) in
the RDC group (1 RA, 1 JIA, and 3 AS samples).
These results are summarized in Table 2. The per-
formance of the tests was evaluated, for sensitivity, spe-
cificity, positive likelihood ratio (LR+) and negative
likelihood ratio (LR−), and found to be 14.2%, 99.4%,
23.7, and 0.86, respectively, for anti-rib-P; 9.4% 100%, ∞,
and 0.90, respectively, for anti-Sm ; and 49.6%, 96.9%,
16, and 0.52 for anti-dsDNA.
Only 2 samples (1.6%) were positive for all three tested
autoantibodies, whereas 12 (9.4%) were positive for both
anti-Rib-P and anti-dsDNA, and 7 (5.5%) were positive
for both anti-Sm and anti-dsDNA. Cross-positivity for
anti-Rib-P and anti-Sm was not seen (Table 3).
The relationship between the clinical variables and the
levels of anti-Rib-P, anti-Sm, and anti-dsDNA autoanti-
bodies was further analyzed for the SLE group (Table 4).
Anti-Rib-P levels were related at (P ≤ 0.20) in univa-
riate analysis with age (β = −0.125), Caucasian ethnicity
(β = −0.190), erythrocyte sedimentation rate (ESR;




Anti-Rib-P (U/ml) 4.9 ± 20.2 0.07 ± 0.21 0.016 0.6 ± 1.8 0.017
Anti-Rib-P(+), n (%) 18 (14.2%) 0 (0%) <0.001 2 (0.8%) <0.001
Anti-Sm (U/ml) 2.7 ± 13.8 0.02 ± 0.11 0.028 0.1 ± 0.3 0.035
Anti-Sm(+), n (%) 12 (9.4%) 0 (0%) <0.001 0 (0%) ) <0.001
Anti-dsDNA (U/ml) 44.6 ± 73.8 3.5 ± 8.1 <0.001 2.6 ± 4.2 <0.001
Anti-dsDNA(+), n (%) 63 (49.6%) 6 (6.0%) <0.001 5 (2.0%) <0.001
Abbreviations: Anti-dsDNA, anti-double-stranded DNA; anti-Rib-P, anti-
ribosomal P; anti-Sm, anti-Smith; SLE, systemic lupus erythematosus. Values
represent mean ± standard deviation for concentrations in U/ml and
proportions of positives. Differences were assessed using the t-test for
continuous variables or the χ2 or Fisher’s exact test for proportions.rash (β = 0.142), renal disorder (β = 0.153), hematologic
disorder (β = 0.130), and current corticosteroid dosage
(β = 0.119). Hence, these variables were included in the
multivariate analysis, which showed that Caucasian eth-
nicity (β = −0.190, P = 0.034) was the only factor inde-
pendently associated with anti-Rib-P levels in patients
with SLE (Table 4). Anti-Rib-P antibodies were not asso-
ciated with previous neurologic disorder (seizure or psy-
chosis) or with the occurrence of neuropsychiatric lupus
features within the subsequent 3 years of follow-up.
The variables potentially associated with anti-Sm levels
from the univariate analysis (at P ≤ 0.20) were Caucasian
ethnicity (β = −0.060), ESR (β = 0.203), C-reactive pro-
tein (CRP) (β = 0.372), SLEDAI2K (β = 0.125), malar rash
(β = −0.138), photosensitivity (β = 0.148), serositis (β =
0.277), renal disorder (β = 0.176), anti-RNP antibodies
(β = 0.304), current corticosteroid dosage (β = 0.164),
and use of immunosuppressants (β = 0.209). Higher CRP
levels (β = 0.304, P = 0.003), serositis (β = 0.321; P = 0.002),
and previous positivity for anti-RNP antibodies (β = 0.297;
P = 0.003) were found to be independently associated with
anti-Sm levels in patients with SLE (Table 4).
For anti-dsDNA levels, age (β = −0.237), age at disease
onset (β = −0.169), disease duration (β = −0.176), ESR
(β = 0.187), SLEDAI2K (β = 0.413), arthritis (β = −0.150),
renal (β = 0.287), hematologic (β = 0.259), and immuno-
logic disorders (β = 0.186), and current corticosteroid
dosage (β = 0.130) came out as candidate predictors for
higher anti-dsDNA levels (at P ≤ 0.20 in univariate ana-
lysis).In the multivariate analysis, SLEDAI2K (β = 0.338;Table 3 Cross-positivity for the three determined
autoantibodies (anti-Rib-P, anti-Sm, and anti-dsDNA) in
patients with SLE
Positive for: n %
None 57 44.9
Anti-Rib-P only 4 3.1
Anti-Sm only 3 2.4
Anti-dsDNA only 42 33.1
Anti-Rib-P & Anti-Sm 0 0
Anti-Rib-P & Anti-dsDNA 12 9.4
Anti-Sm & Anti-dsDNA 7 5.5
All three autoantibodies 2 1.6
Abbreviations: Anti-dsDNA, anti-double-stranded DNA; anti-Rib-P, anti-
ribosomal P; anti-Sm, anti-Smith; SLE, systemic lupus erythematosus.
Table 4 Clinical variables associated with anti-Rib-P, anti-Sm and anti-dsDNA levels in patients with SLE
Variables Anti-Rib-Pa Anti-Smb Anti-dsDNAc
β coefficient P β coefficient P β coefficient P
Ethnicity (Caucasian) −0.190 0.034
CRP, mg/dl 0.304 0.003
Presence of serositisd 0.321 0.002
Anti-RNP positive 0.297 0.003
Disease duration, years −0.246 0.005
SLEDAI2K 0.338 <0.001
Presence of renal disorderd 0.252 0.004
Abbreviations: Anti-dsDNA, anti-double-stranded DNA; anti-Rib-P, anti-ribosomal P; anti-RNP: anti-ribonucleoprotein; anti-Sm, anti-Smith; CRP: C-reactive protein;
ESR: erythrocyte sedimentation rate; SLE, systemic lupus erythematosus; SLEDAI2K: Systemic Lupus Erythematosus Disease Activity Index 2000. Multivariate
analysis results from multiple linear regression analysis. The total explained variance of the model was aR2 = 0.036, bR2 = 0.325, and cR2 = 0.270. dIn accordance with
American College of Rheumatology classification criteria.
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shorter disease duration (β = −0.246; P = 0.005) were
found to be independently associated with anti-dsDNA
levels (Table 4).
Discussion
Confirming earlier studies, the current work shows that
anti-Rib-P protein autoantibodies are very specific for
SLE diagnosis. The presence of antibodies against ribo-
somal P proteins was found to be very specific for pa-
tients with SLE compared with either HCs or with
controls who had other rheumatic diseases. Moreover,
the test had high levels of specificity and sensitivity.
However, the choice of the most reliable test to deter-
mine these autoantibodies requires a comparative study
between different tests and the study of a larger and
multi-ethnic population.
In addition to determining the levels of anti-Rib-P
autoantibodies, we used the same FEIA detection me-
thod to determine levels anti-Sm and anti-dsDNA auto-
antibodies in the same study groups. Both anti-Sm and
anti-dsDNA antibodies have also been reported to be
very specific for patients with SLE [21-23]; however, we
found that anti-dsDNA antibodies were present at low
levels in 6% of HCs and 2% of RDCs samples.
The commercial kit that we used for the determination
of anti-Rib-P protein (EliA test) is an FEIA, designed as
a sandwich immunoassay, containing a mixture of the
three Rib-P antigens (P0, P1, and P2), which has been
described previously as having high sensitivity and speci-
ficity [7,11,24]. We also used ROC curves to check the
accuracy of this kit for the Portuguese population. ROC
curves can be used to evaluate the diagnostic perform-
ance of a test, adjusting for a particular study popula-
tion, and to determine the capability of a test to allow
discrimination between the positive group and the con-
trol group [25,26]. Based on the ROC curves, we ad-
justed the cut-off values for both anti-Rib-P and anti-Smto 4.45 U/ml and 3.4 U/ml, respectively. These values
corresponded to the lowest concentration that allowed
the highest possible sensitivity without losing specificity,
establishing a cut-off value for the SLE group in com-
parison with the HC and RDC groups. For anti-dsDNA
determination, we used the manufacturer’s cut-off value
(15 U/ml) in subsequent analyses, as this gave the best
combination of sensitivity and specificity. The cut-off
confirmation should be performed when using a new kit
or when using an existing kit in a different population.
The adjusted values might be either higher or lower than
those established by the manufacturer, as confirmed by
the work of Mahler and colleagues [12].
Our results showed increased levels of all the three auto-
antibodies in patients with SLE, and a higher percentage
of positive samples for at least one of the autoantibodies
in the SLE group. Although anti-dsDNA autoantibodies
were present in more individuals in the SLE group than in
the other two groups, the presence of anti-Rib-P or anti-
Sm was more specific for SLE diagnosis.
We reviewed the medical records of the individuals in
the HC and RDC groups who had a positive result for
either anti-Rib-P or anti-dsDNA antibodies (none was
positive for anti-Sm). Both of the anti-Rib-P-positive
results were detected in patients with RA, one of these
patients had presented with some lupus-like characteris-
tics (skin rash, leucopenia, and aphthous ulcer) at some
point in the disease course, and thus this case could be
classified as an overlap RA/SLE. Interestingly, a similar case
was previously reported, referring to a anti-Rib-P-positive
patient with RA, who later developed renal disease, and
their condition evolved into full-blown SLE [11]. None of
our HC or RDC group who were positive for anti-dsDNA
autoantibodies had presented any lupus-like characteristics
at any time.
When we used multivariate analysis on our SLE group,
the only independent association with anti-Rib-P anti-
bodies we identified was ethnicity: lower anti-Rib-P levels
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knowledge, no previous reports have established this as-
sociation. However, given the small number of non-
Caucasian patients in our group, these findings need to be
replicated in larger SLE populations with different ethnic
backgrounds.
Many previous studies have reported a relationship be-
tween the presence of anti-Rib-P antibodies and that of
some clinical features, namely malar rash, renal involve-
ment, and neuropsychiatric events, particularly psychosis
[8,11,27,28]. However, there are also reports that corro-
borate our findings of an absence of such an association
between the presence of anti-Rib-P antibodies and clini-
cal features or disease activity [7,13,16]. In addition, our
analysis differed from previous reports because we also
took into consideration anti-Rib-P levels.
We found that Rib-P positivity was not associated with
previous neuropsychiatric features classifiable by the ACR
criteria [29,30], and the presence of these autoantibodies
did not have a predictive value for the occurrence of
neuropsychiatric symptoms in the subsequent 3 years.
Thus, these autoantibodies seem to be very specific for
SLE, but their value for diagnosis of neuropsychiatric
lupus seems to be limited, possibly because both anti-Rib
-P positivity and neuropsychiatric symptoms are relatively
rare. However, given the high specificity, the inclusion of
these autoantibodies as part of the SLE classification cri-
teria might be useful. To confirm this, further studies
encompassing a larger and multi-ethnic population are
needed. Besides its possible use in established SLE, it will
be important to assess the performance of such a test in
patients with early-stage disease to confirm whether the
inclusion of anti-Rib-P testing can improve diagnostic ac-
curacy for SLE.
We performed a multivariate analysis for anti-Sm and
anti-dsDNA levels, which revealed some associations of
these antibodies with features of the disease. Serositis and
CRP levels were positively associated with higher anti-Sm
levels. High CRP levels are usually associated with an on-
going infection in patients with SLE, although they have
been also associated with serositis, independently of the
existence of an infection [31,32]. This is in line with our re-
sults, as we found that CRP levels were increased in pa-
tients with serositis (P = 0.047). However, the association
between serositis and anti-Sm antibodies contradicts the re-
sults of a previous report from Wang and co-workers [33].
The multivariate analysis also showed anti-RNP levels
to be independently associated with anti-Sm levels. Both
anti-Sm and anti-RNP antibodies recognize complexes
that contain small nuclear RNA species, and the occur-
rence of anti-Sm antibodies along with anti-RNP anti-
bodies has been reported previously [34].
Our observations regarding anti-dsDNA are in line
with other classic findings depicting an association withrenal involvement, as well as in relation to lower disease
duration and higher disease activity [35].
We also evaluated cross-positivity for the three studied
autoantibodies, and verified that 78% of the anti-Rib-P-
positive patients were also positive for one or both of
the other antibodies determined. Previous studies have
also shown that the presence of anti-Rib-P antibodies is
often associated with anti-dsDNA antibodies, but the
simultaneous presence of anti-Rib-P and anti-Sm is not
consensual between studies [2,8,11,13]. However, we
found that four patients (3.1%) in our SLE group (22% of
the anti-Rib-P-positive patients) were positive for anti-
Rib-P autoantibodies only. We reviewed the clinical re-
cords of these four patients, and found no particular
clinical features in common.
Conclusions
The presence of anti-Rib-P antibodies in patients negative
for anti-DNA and anti-Sm indicates that these autoanti-
bodies might be useful for SLE diagnosis, as previously
reported by Mahler and colleagues [10]. Based on previous
suggestions by other authors, and considering that disease
classification criteria are constantly subject to confirmation
and re-evaluation studies, as recently published by Petri
and colleagues [36], we propose that further studies should
be performed to evaluate the relevance of anti-Rib-P anti-
body testing for SLE diagnosis.
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